[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636554":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":47,"collaborators":50,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":55,"sex":61,"minAge":62,"maxAge":7,"enrollmentInfo":63,"targetDuration":7,"studyType":66,"phases":7,"briefSummary":67,"conditions":68,"keywords":73,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Universita degli Studi di Genova","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Andrea Bianconi, MD","CONTACT","+393475805577","andrea.bianconi@unige.it",[15,34],{"facility":16,"status":17,"city":18,"state":19,"zip":20,"country":21,"countryCode":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":29},"AOU Città della Salute e della Scienza","RECRUITING","Torino","Turin","10126","Italy","IT",{"type":24,"coordinates":25},"Point",[26,27],11.99138,44.88856,{"lat":27,"lon":26},[30],{"name":31,"role":11,"phone":32,"phoneExt":7,"email":33},"Fabio Cofano, Md","0116335427","fabio.cofano@unito.it",{"facility":35,"status":17,"city":36,"state":7,"zip":37,"country":21,"countryCode":22,"cosmosGeoPoint":38,"geoPoint":42,"contacts":43},"IRCCS Azienda Ospedaliera Metropolitana","Genova","16100",{"type":24,"coordinates":39},[40,41],11.87211,45.21604,{"lat":41,"lon":40},[44],{"name":45,"role":11,"phone":46,"phoneExt":7,"email":13},"Andrea Bianconi","3475805577",{"type":48,"investigatorFullName":45,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Assistant Professor",[51],{"name":52,"class":6},"University of Turin, Italy","100636554","pet-guided-resection-in-high-grade-gliomas-100636554",false,"NCT07567196","PET-Guided Resection in High-Grade Gliomas","ResPGlioma: Impact of PET-Guided Resection on Survival in High-Grade Gliomas - A Multicenter Prospective Study","ResPGlioma","Inclusion Criteria:\n\n* age ≥18 years\n* high-grade glioma (WHO grade III\u002FIV) diagnosed on MRI\n* provide written informed consent\n\nExclusion Criteria:\n\n* tumors located in the cerebellum, brainstem, or midline.\n* Patients with medical conditions precluding MRI\n* inability to provide written informed consent\n* secondary high-grade gliomas resulting from malignant transformation of a low-grade glioma\n* other primary malignancy within the past five years","ALL","18 Years",{"count":64,"type":65},100,"ESTIMATED","OBSERVATIONAL","Background: Glioblastoma (GBM) is the most common primary brain tumor in adults, with a poor prognosis despite maximal treatment. Current evidence suggests that supramaximal resection, including non-enhancing FLAIR-hyperintense regions, improves survival. However, the extent of FLAIR resection is often limited by functional constraints and its non-specific nature, as it may represent both tumor infiltration and peritumoral edema. This study explores the role of 18F-DOPA PET in refining supramaximal resection by providing a more specific surgical target beyond contrast-enhancing areas.\n\nObjective: To evaluate the impact of 18F-DOPA PET-guided resection on progression-free survival (PFS) and overall survival (OS) in GBM patients, by comparing outcomes between those undergoing PET-RM integrated resection versus conventional MRI-guided resection.\n\nMethods: ResPGlioma is a multicenter, prospective, non-randomized study conducted at IRCCS Ospedale Policlinico San Martino (Genoa) and AOU Città della Salute e della Scienza (Turin). Patients with newly diagnosed, supratentorial, high-grade gliomas undergo preoperative 18F-DOPA PET and MRI. Surgery follows the principle of maximal safe resection, with postoperative MRI at 48 hours assessing the extent of resection (EOR). To confirm PET resection or non-PET resection status, patients will undergo a postoperative 18F-DOPA PET scan at 30 ± 7 days following surgery, prior to the initiation of chemoradiotherapy. Patients are categorized based on EOR criteria (RANO) and PET volume resection (PET-resection vs. PET non-resection). Statistical analyses include Kaplan-Meier survival curves and regression models to identify prognostic factors.Patients are categorized based on EOR criteria (RANO) and PET volume resection (PET-resection vs. PET non-resection). Statistical analyses include Kaplan-Meier survival curves and regression models to identify prognostic factors.\n\nExpected Outcomes: The authors hypothesize that PET-guided resection improves PFS and OS by enabling a more precise tumor removal beyond contrast-enhancing margins while preserving neurological function. Preliminary data support that PET hypercaptant areas contain viable tumor cells and should be resected. This approach may offer a more accessible yet effective alternative to FLAIR-guided supramaximal resection.",[69,70,71,72],"Glioma Glioblastoma Multiforme","Glioma, High Grade","Glioma Surgery","Positron-Emission Tomography(PET)",[74,75,76],"glioma","glioblastoma","PET","2026-04-27",{"date":79,"type":80},"2026-05-05","ACTUAL",{"date":82,"type":80},"2022-04-01",{"date":84,"type":65},"2029-12-31",{"name":5,"class":6},2]